Articles

31. Proven Treatment Value Commercial Solutions 5/13/2011
    For every biopharma company, it’s the ultimate goal—a drug that delivers demonstrable patient benefits, that physicians recommend and prescribe, and whose cost/ benefit profiles payers endorse.
32. TQT Solutions 5/11/2011
    The increasingly complex regulatory environment has focused an intense spotlight on cardiac safety. You now have to produce more evidence with greater accuracy for the full spectrum of therapeutic areas.
33. Case Study: Flu Vaccine Trial Accelerated Despite Late-In-Season Start 5/11/2011
    Streamlined processes for study startup, coupled with experience in vaccine trials and solid relationships with study sites and investigators, helped this Quintiles team meet the challenge of starting an influenza vaccine trial late in the influenza season.
34. Targeting Oncology 5/11/2011
    In the search to improve cancer outcomes, each promising advance across the biopharmaceutical frontier comes with challenges as unique as the specific molecular pathway and individual genetic profile it targets.
35. Case Study: Post-Marketing Commitment Study 5/11/2011
    Pharmaceutical companies are feeling the pressure of a new level of regulatory scrutiny surrounding post-marketing commitment studies.
36. A Focus On CNS (Central Nervous System) 5/11/2011
    Today, developing differentiated drugs that deliver demonstrable patient benefits and added value is more challenging than ever.
37. White Paper: The Art Of Compliance - Turning Compliance Into A Sustainable Business Advantage 5/11/2011
    The past few years have presented extraordinary regulatory and quality compliance challenges for pharmaceutical, biotechnology, and medical device companies. They are required to do more with less as a result of consolidation, restructuring, and economic uncertainty.
38. Late Phase Research 5/11/2011
    The post-marketing environment is evolving rapidly — and without the right strategy, new challenges can squeeze precious value out of your investment.
39. Early Clinical Development Solutions 5/11/2011
    In the New Health, where competition and technology are driving rapid change, dollars and potential delays matter more than ever. Making the right decisions in early development is critical to the success of your portfolio.
40. Data Driven Market Success 5/11/2011
    A Quintiles customer needed an experienced post-marketing ally who could plan for the unknown and design an observational study to eventually include several affiliates, thousands of sites, and more than 55,000 patients, with start-ups staggered over time.